A series of workshops in a huge variety of topics, divided among four sections: arts & crafts; food; health and lifestyle; and know-how.

Adobe Flash Player is required to view this feature. If you are using an operating system that does not support Flash, we are working to bring you alternative formats. Original Article Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, M.D., Ph.D., Vanna Chiarion-Sileni, M.D., Rene Gonzalez, M.D., Jean Jacques Grob, M.D., C.

Lance Cowey, M.D., Christopher D. Lao, M.D., M.P.H., Dirk Schadendorf, M.D., Reinhard Dummer, M.D., Michael Smylie, M.D., Piotr Rutkowski, M.D., Ph.D., Pier F.

Ferrucci, M.D., Andrew Hill, M.D., John Wagstaff, M.D., Matteo S. Carlino, M.D., John B. Haanen, M.D., Michele Maio, M.D., Ph.D., Ivan Marquez-Rodas, M.D., Ph.D., Grant A. McArthur, M.D., Paolo A.

Ascierto, M.D., Georgina V. Long, M.D., Margaret K. Callahan, M.D., Ph.D., Michael A. Postow, M.D., Kenneth Grossmann, M.D., Mario Sznol, M.D., Brigitte Dreno, M.D., Lars Bastholt, M.D., Arvin Yang, M.D., Ph.D., Linda M. Rollin, Ph.D., Christine Horak, Ph.D., F. Stephen Hodi, M.D., and Jedd D. Wolchok, M.D., Ph.D.

N Engl J Med 2015; 373:23-34 DOI: 10.1056/NEJMoa1504030. Results The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P.

Figure 1 Progression-free Survival. Panel A shows the Kaplan–Meier curves for progression-free survival in the intention-to-treat population. Patients were followed for a minimum of 9 months. The median progression-free survival was 6.9 months (95% CI, 4.3 to 9.5) in the nivolumab group, 11.5 months (95% CI, 8.9 to 16.7) in the nivolumab-plus-ipilimumab group, and 2.9 months (95% CI, 2.8 to 3.4) in the ipilimumab group. Download Bbm2 Mod Versi Terbaru Apk on this page. Significantly longer progression-free survival was observed in the nivolumab-plus-ipilimumab group than in the ipilimumab group (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P. Figure 2 Tumor-Burden Change in Target Lesions. The waterfall plots show the maximum change from baseline in the sum of the reference diameters of the target lesion in patients receiving nivolumab (Panel A), nivolumab plus ipilimumab (Panel B), or ipilimumab (Panel C).

Data are shown for all the patients who had target lesions evaluated at baseline and who underwent at least one tumor assessment during treatment. The percentage increase was truncated at 100% (rectangles). Ivete Sangalo Madison Square Torrent more.

Asterisks indicate patients who had a response to treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. The horizontal dashed lines indicate a 30% reduction in the tumor burden in the target lesion, and the vertical dashed lines indicate the inflection point for the nivolumab-plus-ipilimumab group. The change in tumor burden was defined as the percentage decrease in the sum of the reference diameters of the target lesion from baseline to nadir, observed up until the date of progression, as assessed by the investigator per RECIST, version 1.1, the date of subsequent anticancer therapy (including tumor-directed radiotherapy and tumor-directed surgery), or death, whichever occurred first. Considerable progress in the treatment of metastatic melanoma has been made in the past 5 years, with the approval of immune checkpoint–blocking antibodies and, in parallel, agents targeting aberrant signaling in the 40 to 50% of melanomas with BRAF mutations. Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody, acts to up-regulate antitumor immunity and was the first agent to be associated with an improvement in overall survival in a phase 3 study involving patients with metastatic melanoma. Ipilimumab was associated with responses in 10% and 15% of patients; approximately 20% of treated patients had long-term survival. Two anti–programmed death 1 (PD-1) antibodies, nivolumab and pembrolizumab, were approved by the Food and Drug Administration in 2014 for the treatment of metastatic melanoma after progression during ipilimumab treatment and, in patients with BRAF-mutated melanoma, after progression during treatment with a BRAF inhibitor.

These antibodies were associated with objective responses in 30 to 40% of patients, with the majority of responses being durable. Two phase 3 trials have shown superior efficacy of nivolumab, as compared with chemotherapy, in previously untreated patients with wild-type BRAF tumors or in patients with either mutant or wild-type BRAF tumors after progression during ipilimumab therapy and, in patients with tumors positive for BRAF mutation, after progression during treatment with a BRAF inhibitor. Similar results were observed in a phase 2 trial of pembrolizumab versus chemotherapy. Recently, pembrolizumab was associated with longer progression-free survival and overall survival and higher response rates than those associated with ipilimumab in a phase 3 trial involving patients with advanced melanoma. The results of a phase 2 study that compared combined nivolumab and ipilimumab with ipilimumab alone in patients with BRAF wild-type melanoma showed objective response rates of 61% with the combination therapy and 11% with the monotherapy, with complete responses in 22% and 0% of patients, respectively. Treatment-related adverse events of grade 3 or 4 were reported in 54% of the patients in the combination group and in 24% of those in the ipilimumab group.